Treating the liver by starting somewhere else entirely

Metabolic dysfunction-associated steatohepatitis, or MASH, has become one of the harder problems in hepatology to solve, despite affecting an estimated 7% of people worldwide. It's a severe form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure, and treatment options have remained genuinely limited even as newer drugs have entered the market. A team at Michigan Medicine, the University of Michigan's academic medical center, just published research in The Journal of Clinical Investigation describing an experimental compound that takes a considerably different approach to the problem: rather than targeting the liver directly, it works by repairing the gut.

The compound, called DT-109, is a glycine-based tripeptide — a small molecule built from three amino acids. Researchers led by senior author Dr. Eugene Chen, the Frederick G.L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School, had already shown in earlier studies that DT-109 could improve MASH outcomes in animals. This new research set out to answer a more specific question: exactly how was it producing that benefit, and could understanding the mechanism reveal something useful about the disease itself.

A bacterial culprit hiding in the gut

The mechanism the team uncovered centers on a specific gut bacterium: Clostridium perfringens. In MASH, harmful bacterial byproducts — ammonia chief among them — appear to leak from a damaged, weakened intestinal barrier into the broader bloodstream, eventually reaching and damaging the liver. That's a meaningfully different disease model than one focused purely on liver fat accumulation or inflammation occurring independently within the organ itself. It frames MASH, at least in part, as a disorder that begins with a breakdown in gut barrier integrity, with the liver damage arriving as a downstream consequence of what's leaking through from the intestines.

Chen described the evidence directly: "We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression." That's a specific, testable claim about mechanism, not a vague description of general health improvement — the compound is protecting a physical barrier, and that protection is what's limiting how much bacterial toxin ultimately reaches the liver.

What happened when researchers tested the compound directly

Through a series of experiments, Chen's team found that DT-109 interrupted this gut-to-liver damage pathway in two measurable ways: reducing Clostridium perfringens levels in the intestines, and lowering the associated ammonia production those bacteria generate. With less bacterial toxin being produced in the first place, and a strengthened intestinal barrier limiting how much of it could escape into systemic circulation, the downstream damage to the liver was correspondingly reduced.

This effect held across two different animal models — mice and nonhuman primates — which matters for how seriously the findings should be taken. Mouse models are useful for initial mechanistic screening, but their liver biology and gut microbiota composition differ meaningfully from humans in ways that sometimes cause promising mouse results to fail entirely when tested in more human-like systems. Nonhuman primates, whose liver biology and gut microbiota composition more closely resemble those of humans, provide a considerably stronger signal about whether a mechanism observed in mice is likely to hold up in people.

The primate results were the most encouraging piece

That distinction is exactly why the nonhuman primate results carry particular weight in this study. In these animals, DT-109 reduced liver inflammation and significantly improved the severity of MASH, according to Michigan Medicine's own reporting on the findings. Seeing the mechanism play out consistently in a model biologically closer to humans is a meaningfully stronger piece of evidence than mouse data alone would provide, though it's still a considerable step removed from confirming the same effect in actual human patients.

Chen framed the broader clinical potential in direct terms: "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH." That's an appropriately measured claim for a compound that has demonstrated a clear mechanism and consistent benefit across two animal models, without yet having been tested in human clinical trials for this specific application.

A disclosed financial interest worth noting

It's worth being transparent about one detail in how this research was conducted: Chen and the University of Michigan hold an ownership interest in Diapin, the company that provided DT-109 for this study and is continuing to develop the compound. That's a standard and disclosed conflict-of-interest arrangement common in translational academic research, where researchers who discover a promising compound often retain a financial stake in its future commercial development. It doesn't invalidate the findings, which were published through the peer-review process at The Journal of Clinical Investigation, but it's a relevant detail for readers evaluating how the research and its eventual commercial path are connected.

Why the gut-liver framing might matter beyond this one drug

The significance of this study extends beyond DT-109 itself. If a meaningful share of MASH progression really is driven by specific gut bacteria compromising intestinal barrier integrity and leaking toxins into systemic circulation, that reframes where researchers might look for future treatments entirely. Rather than focusing exclusively on drugs that act directly on liver cells — reducing fat accumulation, calming inflammation, or slowing fibrosis within the organ itself — this research points toward an entirely separate category of intervention: therapies aimed at gut bacterial populations and intestinal barrier function, positioned upstream of the liver damage rather than treating it after the fact.

That's a potentially significant expansion of the therapeutic toolkit for a disease that has had frustratingly few effective treatment options. Whether DT-109 itself eventually clears human clinical trials remains genuinely uncertain — promising mechanisms in animal models, even nonhuman primates, don't always translate cleanly into approved human therapies. But the gut-liver axis this research illuminates gives MASH researchers a new direction to pursue, independent of how this particular compound's own development path unfolds.

*This article was researched using publicly available reporting from The Journal of Clinical Investigation, Michigan Medicine, ScienceDaily, Medical Xpress, News-Medical, Newswise, and EurekAlert coverage of the peer-reviewed study led by Dr. Eugene Chen. It is intended for informational purposes and is not medical advice.*